Pharm cancer IV Flashcards
imatinib class
tyrosine kinase inhibitor (CML)
imatinib mechanism
inhibits abl kinase by binding where ATP should go; also inhibits PDGFR and c-kit; metabolized by cytochrome P450
imatinib side effects
nausea, vomiting, fluid retention, muscle cramps, arthralgia
rituximab mechanism
CD20 B-cell antibody that can directly activate apoptosis, complement, or cell-mediated cytotoxicity (non-hodgkin’s lymphomas)
rituximab side effects
infusion reactions, tumor lysis syndrome, severe mucocutaneous reactions, progressive multifocal leukoencephalopathy
trastuzumab mechanism
HER2/neu receptor antibody mechanism
trastuzumab side effects
hypersensitivity reaction; ventricular dysfunction
ado-trastuzumab emtansine (kadcyla) class
antibody-drug conjugate
ado-trastuzumab emtansine (kadcyla) mechanism
conjugate undergoes receptor-dependent internalization and drug is released inside the cell
ado-trastuzumab emtansine (kadcyla) side effects
fatigue, nausea, musculoskeletal pain, thrombocytopenia, headache, hypokalemia, peripheral neuropathy, ventricular dysfunction, interstitial lung disease
nivolumab mechanism
antibody that prevent T cell from turning off by inhibiting programmed cell death protein 1
nivolumab side effects
rash, itching, couch, upper resp tract infections, edema, fatigue, SOB, musculoskeletal pain, decreased appetite, nausea, consitpation
vemurafenib class
serine/threonine kinase inhibitor
vemurafenib mechanism
inhibits oncogenic BRAF kinase`
vemurafenib side effects
arthralgia, fatigue, photosensitivity, nausea, alopecia, diarrhea, QT prolongation
dabrafenib class
serine/threonine kinase inhibitor
dabrafenib mechanism
inhibits oncogenic BRAF kinase
dabrafenib side effects
serious febrile drug reactions, uveitis and iritis, hyperglycemia, hyperkeratosis
trametinib class
dual specificty kinase
trametinib mechanism
inhibits MEK
trametinib side effects
cardimyopathy, retinal disorders, interstitial lung disease, serious skin toxicities
